Key facts
- This page summarizes David J. Grainger's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2024, 19:41.
David J. Grainger - 31 Dec 2023 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Chief Innovation Officer
- Issuer ticker
- CNTA
- Reported as of
- 31 Dec 2023
- Net transaction value
- -$37,412
- SEC form
- 4
- Accepted by SEC
- 02 Jan 2024, 19:41:07 UTC
- Prior SEC filing
- 03 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory Weinhoff, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David J. Grainger filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 02 Jan 2024.
Change
- Previous filing in this sequence was filed on 03 Oct 2023.
- Current net transaction value: -$37,412.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTA
transaction
Ordinary Shares
Tax liability
- Transaction value
- $37,412
- Shares
- -4,700
- Change %
- -0.49%
- Price
- $7.96
- Shares after
- 962,790
- Date
- 31 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CNTA
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 27,500
- Date
- 31 Dec 2023
- Ownership
- See footnote
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David J. Grainger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
Footnote F3
Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.